Ultragenyx Pharmaceutical | RARE - Net Income


Ultragenyx Pharmaceutical reported $-185M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Acadia Pharmaceuticals USD 31.5M 27.86M Jun/2026
Agios Pharmaceuticals USD -99.11M 8.93M Mar/2026
Alnylam Pharmaceuticals USD 164.49M 41.5M Jun/2026
BioCryst Pharmaceuticals USD 78.4M 167.45M Jun/2026
BioMarin Pharmaceutical USD 105.53M 152.1M Mar/2026
Immunic USD -19.3M 6.28M Dec/2025
Insmed USD -163.56M 164.92M Mar/2026
Ionis Pharmaceuticals USD -114.65M 21.65M Jun/2026
Karyopharm Therapeutics USD -22.39M 79.81M Mar/2026
Kyowa Hakko Kirin JPY 18.58B 6.55B Jun/2026
MacroGenics USD -36.77M 22.62M Mar/2026
Moderna USD -1.34B 517M Mar/2026
Neurocrine Biosciences USD 144.4M 53.5M Jun/2026
PTC Therapeutics USD -2.81M 132.16M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 1.3B 569.7M Jun/2026
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
Vertex Pharmaceuticals USD 1.1B 68.4M Jun/2026